Search research articles
Contact Us
Filters
Showing results (1-10 of 26) with videos related to
Page
of 3
Sort By:
Experimental Hematology & Oncology
|
August 26, 2023
Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting
Jiangxue Hou, Yufu Li, Quande Lin
Molecular Cancer
|
November 6, 2019
Recent updates on CAR T clinical trials for multiple myeloma
Quande Lin, Juanjuan Zhao, Yongping Song, et al.
Journal of Hematology & Oncology
|
November 29, 2018
Universal CARs, universal T cells, and universal CAR T cells
Juanjuan Zhao, Quande Lin, Yongping Song, et al.
Biomarker Research
|
July 2, 2025
Emerging therapeutic agents in multiple myeloma: highlights from the 2024 ASH annual meeting
Qing Zhang, Yongping Song, Keshu Zhou, et al.
Experimental Hematology & Oncology
|
March 27, 2025
Mechanisms of resistance to CAR-T cell therapy in multiple myeloma: latest updates from the 2024 ASH annual meeting
Yuhan Hu, Jiangxue Hou, Zhongxing Jiang, et al.
Frontiers in Oncology
|
January 6, 2025
Molecular glue degrader for tumor treatment
Yuhan Hu, Yan Yan, Jiehao Wang, et al.
Cell Cycle (Georgetown, Tex.)
|
November 2, 2020
Depletion of circ_0007841 inhibits multiple myeloma development and BTZ resistance via miR-129-5p/JAG1 axis
Yan Wang, Quande Lin, Chunge Song, et al.
Oncology Letters
|
December 2, 2015
Primary skeletal muscle diffuse large B cell lymphoma: A case report and review of the literature
Lijuan Zhang, Quande Lin, Lina Zhang, et al.
Frontiers of Medicine in China
|
February 22, 2014
Pluripotent stem cells exhibiting similar characteristics can be isolated from human fetal bone marrow, heart, liver, muscle, lung, derma, kidney, and fat
Baijun Fang, Yongping Song, Chunhua Zhao, et al.
Cancer Cell International
|
August 13, 2020
Circ_0007841 promotes the progression of multiple myeloma through targeting miR-338-3p/BRD4 signaling cascade
Yan Wang, Quande Lin, Chunge Song, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 26) with videos related to
Sort By:
Page
of 3
Experimental Hematology & Oncology
|
August 26, 2023
Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting
Jiangxue Hou, Yufu Li, Quande Lin
Molecular Cancer
|
November 6, 2019
Recent updates on CAR T clinical trials for multiple myeloma
Quande Lin, Juanjuan Zhao, Yongping Song, et al.
Journal of Hematology & Oncology
|
November 29, 2018
Universal CARs, universal T cells, and universal CAR T cells
Juanjuan Zhao, Quande Lin, Yongping Song, et al.
Biomarker Research
|
July 2, 2025
Emerging therapeutic agents in multiple myeloma: highlights from the 2024 ASH annual meeting
Qing Zhang, Yongping Song, Keshu Zhou, et al.
Experimental Hematology & Oncology
|
March 27, 2025
Mechanisms of resistance to CAR-T cell therapy in multiple myeloma: latest updates from the 2024 ASH annual meeting
Yuhan Hu, Jiangxue Hou, Zhongxing Jiang, et al.
Frontiers in Oncology
|
January 6, 2025
Molecular glue degrader for tumor treatment
Yuhan Hu, Yan Yan, Jiehao Wang, et al.
Cell Cycle (Georgetown, Tex.)
|
November 2, 2020
Depletion of circ_0007841 inhibits multiple myeloma development and BTZ resistance via miR-129-5p/JAG1 axis
Yan Wang, Quande Lin, Chunge Song, et al.
Oncology Letters
|
December 2, 2015
Primary skeletal muscle diffuse large B cell lymphoma: A case report and review of the literature
Lijuan Zhang, Quande Lin, Lina Zhang, et al.
Frontiers of Medicine in China
|
February 22, 2014
Pluripotent stem cells exhibiting similar characteristics can be isolated from human fetal bone marrow, heart, liver, muscle, lung, derma, kidney, and fat
Baijun Fang, Yongping Song, Chunhua Zhao, et al.
Cancer Cell International
|
August 13, 2020
Circ_0007841 promotes the progression of multiple myeloma through targeting miR-338-3p/BRD4 signaling cascade
Yan Wang, Quande Lin, Chunge Song, et al.
Page
of 3